Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454505 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AL-53817 Nasal Spray Solution
A Phase 1 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT01454505 is a Phase 1 study that has completed, run by Alcon Research. The registered enrollment target is 110 participants.
The verdict
NCT01454505, a Phase 1 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
Interventions
- DRUG AL-53817 nasal spray solution
- OTHER Vehicle nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454505
The ClinicalTrials.gov registry entry for NCT01454505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AL-53817 nasal spray solution is the first listed.
NCT01454505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454505 about?
NCT01454505 is a clinical study titled "Safety and Efficacy of AL-53817 Nasal Spray Solution". The purpose of this study was to determine the maximum tolerated dose of AL-53817 (Stage A) and evaluate the safety and efficacy of AL-53817 for the treatment of allergic rhinitis (Stage B).
What is the current status of trial NCT01454505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2011-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01454505?
The interventions under investigation include: AL-53817 nasal spray solution (DRUG), Vehicle nasal spray (OTHER).
Who is sponsoring clinical trial NCT01454505?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.